<DOC>
	<DOC>NCT00401401</DOC>
	<brief_summary>The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer</brief_summary>
	<brief_title>Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Squamous Cell</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients with locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx Prior treatment with radiotherapy in the head and neck area Prior treatment with chemotherapy Prior treatment with similar drugs (e.g. EGFr antibodies, EGFr inhibitors) Previous surgery with curative intent for head and neck cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>